探讨恩替卡韦联合复方鳖甲软肝片治疗乙肝肝硬化的临床疗效

Exploration on the clinical effect of entecavir combined with Compound Biejia Ruangan Tablet in the treatment of hepatitis B cirrhosis

目的:探讨恩替卡韦联合复方鳖甲软肝片治疗乙肝(HCV)肝硬化的临床疗效。方法:2018年2月-2019年3月收治HCV合并肝硬化患者66例,分为两组,各33例。对照组应用恩替卡韦治疗;观察组应用恩替卡韦辅以复方鳖甲软肝片。比较两组治疗前后肝功能数据及治疗后效果。结果:观察组治疗后肝功能数据显著优于对照组,总有效率显著优于对照组,观察组治疗1年后LSM、PTA及Child-Pugh显著优于对照组,差异均有统计学意义(P<0.05)。结论:应用恩替卡韦结合复方鳖甲软肝片治疗HCV肝硬化,效果及预后理想。

Objective:To explore the clinical effect of entecavir combined with Compound Biejia Ruangan Tablet in the treatment of hepatitis B cirrhosis.Methods:From February 2018 to March 2019,66 patients with hepatitis B and cirrhosis were selected,they were divided into the two groups with 33 cases in each group.The control group was treated with entecavir.The observation group was treated with entecavir and Compound Biejia Ruangan Tablet.The data of liver function before and after treatment and the effect after treatment were compared between the two groups.Results:The liver function data of the observation group was significantly better than that of the control group after treatment,and the total effective rate was significantly better than that of the control group.After one year of treatment,the observation group had significantly better LSM,PTA,and Child-Pugh than the control group,the differences were statistically significant(P<0.05).Conclusion:The effect and prognosis of entecavir combined with Compound Biejia Ruangan Tablet in the treatment of HCV cirrhosis are ideal.